| 27.53 -0.27 (-0.97%) | 05-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36 | 1-year : | 39.09 |
| Resists | First : | 30.83 | Second : | 33.47 |
| Pivot price | 29.59  |
|||
| Supports | First : | 26.55 | Second : | 22.09 |
| MAs | MA(5) : | 27.95 |
MA(20) : | 30.19 |
| MA(100) : | 25.6 |
MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | 0 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 21.4 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 33.47 | Low : | 13.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LBRX ] has closed above bottom band by 23.9%. Bollinger Bands are 71% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 28.13 - 28.32 | 28.32 - 28.48 |
| Low: | 26.95 - 27.13 | 27.13 - 27.28 |
| Close: | 27.26 - 27.56 | 27.56 - 27.81 |
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Fri, 15 May 2026
TCG Crossover entities report 1.84M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Fri, 15 May 2026
Commodore Capital (LBRX) files Schedule 13G/A reporting 1.97M shares - Stock Titan
Fri, 15 May 2026
Caligan Partners discloses 1.44M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Wed, 13 May 2026
JPMorgan (NYSE: JPM) files amendment showing 1.43M LBRX shares (4.9%) - Stock Titan
Thu, 05 Feb 2026
LB Pharmaceuticals lines up $100M for new depression trial - Stock Titan
Thu, 05 Feb 2026
LB Pharmaceuticals Announces $100.0 Million Private Placement - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 106.6 (%) |
| Shares Short | 3,800 (K) |
| Shares Short P.Month | 2,620 (K) |
| EPS | -1.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | -19.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -20.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|